Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD
Status:
Not yet recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
The primary objectives of this trial are:
1. Efficacy evaluation of amlodipine folic acid tablets:
To assess the effects of amlodipine folic acid tablets 5.8 mg (5 mg amlodipine + 0.8 mg
folic acid)versus amlodipine tablets 5 mg in preventing all-cause stroke in cerebral
small vascular disease (CSVD) patients with hypertension and elevated homocysteine (Hcy)
level.
2. Intensive Antihypertensive Therapy:
To assess the effect of intensive antihypertensive therapy (SBP<130 mmHg) versus standard
antihypertensive therapy (SBP 130-<140 mmHg) in reducing risk of combined
cardio-cerebrovascular events in CSVD patients with hypertension and elevated Hcy level,
using two basic anti-hypertensive drugs, amlodipine tablets 5 mg or amlodipine folic acid
tablets 5.8 mg.
Phase:
Phase 4
Details
Lead Sponsor:
Beijing Tiantan Hospital
Treatments:
Amlodipine Antihypertensive Agents Folic Acid Vitamin B Complex